Skip to main content

Table 1 Univariate analysis for OS and PFS in GBM patients of TCGA database

From: Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients

Variable No. (%) Median OS (months) P Median PFS (months) P
Age (years)     < 0.001   0.007
 ≥ 60 152 (52.96) 11.28   5.82  
 < 60 135 (47.04) 17.79   7.86  
Gender    0.009   0.145
 Male 169 (58.89) 13.35   7.04  
 Female 118 (41.11) 15.65   7.36  
Ethnicity    0.954   0.686
 Hispanic or Latino 5 (2.21) 14.22   5.98  
 Not Hispanic or Latino 221 (97.79) 14.01   7.04  
LANCL2 gene status    0.023   0.123
 Amplification 157 (27.12) 13.78   6.67  
 No alteration 422 (72.88) 14.50   7.20  
EGFR gene status    0.042   0.230
 Amplification 252 (43.52) 14.01   6.84  
 No alteration 327 (56.48) 14.50   7.66  
LANCL2 and EGFR genes status    0.013   0.509
 Co-amplification 156 (26.94) 13.78   6.67  
 No alteration 423 (73.06) 14.53   7.30  
LANCL2 mRNA status    0.224   0.664
 Overexpression 56 (36.36) 13.78   7.04  
 No alteration 98 (63.64) 13.61   5.98  
EGFR mRNA status    0.778   0.136
 Overexpression 75 (48.70) 14.93   6.41  
 No alteration 79 (51.30) 12.95   6.90  
LANCL2 and EGFR mRNA status    0.930   0.689
 Concurrent overexpression 42 (27.27) 15.39   6.41  
 No alteration 112 (72.73) 13.12   6.84